Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.

[1]  Y. Kanakura,et al.  Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. , 2004, Thrombosis and haemostasis.

[2]  G. Hughes,et al.  Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance , 2003, Thrombosis and Haemostasis.

[3]  Y. Kanakura,et al.  Acquired activated protein C resistance is associated with the co‐existence of anti‐prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus , 2002, British journal of haematology.

[4]  Y. Kanakura,et al.  Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. , 2001, Clinical chemistry.

[5]  B. Brenner,et al.  Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. , 2001, The American journal of medicine.

[6]  M. Margaglione,et al.  The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. , 2000, British journal of haematology.

[7]  A. Tsutsumi,et al.  Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. , 2000, Arthritis and rheumatism.

[8]  H. K. Kim,et al.  Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[9]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[10]  J. Merrill,et al.  Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. , 1999, Thrombosis and haemostasis.

[11]  T. Barbui,et al.  Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. , 1999, Blood.

[12]  H. Hemker,et al.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives , 1997, British journal of haematology.

[13]  P. Mannucci,et al.  Inherited Thrombophilia: Part 1 , 1996, Thrombosis and Haemostasis.

[14]  A. Cumming,et al.  Development of resistance to activated protein C during pregnancy , 1995, British journal of haematology.

[15]  R. Roubey.  Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. , 1994, Blood.

[16]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[17]  B. Evatt,et al.  Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.

[18]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[19]  P. D. de Groot,et al.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993, Blood.

[20]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Kanakura,et al.  The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. , 2006, Haematologica.

[22]  P. Joshua,et al.  Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. , 2001, Blood.